A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

PHASE3CompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

December 16, 2020

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
Glioblastoma
Interventions
DRUG

Enzastaurin Hydrochloride

mg

OTHER

Placebo

mg

DRUG

Temozolomide

mg/m\^2

RADIATION

Radiotherapy

Gy

Trial Locations (65)

10016

New York University Medical Oncology Associates, New York

10029

Icahn School of Medicine at Mount Sinai, New York

10065

New York - Presbyterian - Weill Cornell Medical Center, New York

15232

University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh

19104

Penn Medicine - Perelman Center for Advanced Medicine, Philadelphia

27157

Wake Forest Baptist Health - Comprehensive Cancer Center, Winston-Salem

28806

Messino Cancer Centers, Asheville

30322

Winship Cancer Institute of Emory University, Atlanta

33136

Sylvester Comprehensive Cancer Center, Miami

33176

Miami Cancer Institute, Miami

33486

Lynn Cancer Institute, Boca Raton

33612

Moffitt Cancer Center, Tampa

35233

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt - Ingram Cancer Center, Nashville

40202

Norton Cancer Institute - Multidisciplinary Clinic, Louisville

40536

University of Kentucky Markey Cancer Center, Lexington

43210

The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus

48109

University of Michigan Rogel Cancer Center, Ann Arbor

48202

Henry Ford Health System, Detroit

55407

John Nasseff Neuroscience Institute, Minneapolis

55905

Mayo Clinic - Rochester, Rochester

60612

Rush University Medical Center, Chicago

63110

Washington University School of Medicine Center for Advanced Medicine, St Louis

75246

Baylor University Medical Center, Dallas

77030

Lynn Cancer Institute, Houston

University of Texas Health Science Center at Houston (UT Health), Houston

78229

Mays Cancer Center, San Antonio

78705

Austin Cancer Center - Park St. David's, Austin

80045

University of Colorado Hospital Anschutz Cancer Pavilion, Aurora

80220

Blue Sky Neurology, Englewood

84112

University of Utah, Salt Lake City

85013

Barrow Neurological Institute, Phoenix

85259

Mayo Clinic - Arizona, Scottsdale

90048

Cedars-Sinai Medical Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center - Duarte, Duarte

91105

The University of Southern California, Pasadena

92093

University of California San Diego Moores Cancer Center, La Jolla

92868

University of California Irvine Health Chao Family Comprehensive Cancer Center, Orange

94143

University of California San Francisco Helen Diller Family Comprehensive CA Ctr, San Francisco

100070

Beijing Tian Tan Hospital, Capital Medical University, Beijing

100093

Sanbo Brain Hospital, Capital Medical University, Beijing

100730

Peking Union Medical College Hospital, Beijing

110004

Shengjing Hospital - Nanhu Campus, Shenyang

200040

Huashan Hospital Affiliated to Fudan University, Shanghai

230071

First Affiliated Hospital of USTC - Anhui Provincial Hospital, Hefei

300052

General Hospital of Tianjin Medical University, Tianjin

300350

Tianjin Huanhu Hospital, Xianshuigu

430030

Tongji Hospital, Wuhan

510060

Sun Yat-Sen University Cancer Center, Guangzhou

518035

Shenzhen Second People's Hospital, Shenzhen

710038

Tangdu Hospital, Xi'an

06511

Smilow Cancer Hospital - New Haven, New Haven

32224-1865

Mayo Clinic - Jacksonville, Jacksonville

55455-4800

Masonic Cancer Center, Minneapolis

08820

Hackensack Meridian Health - JFK Medical Center, Edison

27599-7055

The University of North Carolina at Chapel Hill, Chapel Hill

17033-0850

Penn State Health Milton S. Hershey Medical Center, Hershey

37203-1625

SCRI - Tennessee Oncology - Nashville - Centennial, Nashville

98109--1023

Seattle Cancer Care Alliance, Seattle

T6G 1Z2

Cross Cancer Institute, Edmonton

V2S OC2

British Columbia Cancer Agency - Abbotsford, Abbotsford

V8R 6V5

British Columbia Cancer Agency - Victoria, Victoria

K1H 8L6

The Ottawa Hospital - General Campus, Ottawa

J1H 5N4

Hôpital Fleurimont, Sherbrooke

S7N 4H4

Saskatoon Cancer Center, Saskatoon

Sponsors
All Listed Sponsors
lead

Denovo Biopharma LLC

INDUSTRY

NCT03776071 - A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 | Biotech Hunter | Biotech Hunter